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Shveta V. Parekh: Chronic escalating heroin withdrawal leads to future enhanced fear learning 
 (Under the direction of Donald T. Lysle) 
Converging evidence suggests opioid abuse can increase the incidence and severity of 
post-traumatic stress disorder (PTSD) in clinical populations. Interestingly, opioid withdrawal 
alone can produce symptoms similar to those of PTSD. Despite this association, the neural 
mechanisms underlying the relationship of opioid abuse, withdrawal, and PTSD is poorly 
understood. The present experiments investigate whether the heroin withdrawal may induce a 
PTSD-like phenotype. Therefore, we developed an animal model of heroin withdrawal which 
consists of a chronic escalating heroin administration paradigm. This paradigm reliably produces 
withdrawal behaviors in rodents. We tested the effect of chronic escalating heroin administration 
and withdrawal regimen on fear learning, and found it acts as a severe stressor to produce 
enhanced fear learning. These data provide further evidence that heroin withdrawal is sufficient 
to produce enhanced fear learning, and suggests a common underlying mechanism between 
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CHAPTER 1: CHRONIC ESCALATING HEROIN WITHDRAWAL LEADS TO 
FUTURE ENHANCED FEAR LEARNING 
 
INTRODUCTION 
One of the most severe psychological disorders induced by stress is post-traumatic stress 
disorder (PTSD), a chronic and debilitating disorder characterized by exaggerated fear and anxiety 
that results from a traumatic experience. PTSD includes a myriad of psychological and 
physiological consequences, some of which include re-experiencing the fear through flashbacks 
or nightmares, avoiding the fear by staying away from places, events, or objects that are reminders 
of the traumatic experience, arousal and reactivity symptoms such as being easily startled or 
feeling tense or stressed and cognition and mood symptoms such as negative thoughts and distorted 
feelings (Rubin, Berntsen et al. 2008, Gill, Saligan et al. 2009, Xia, Zhai et al. 2013, Reardon, 
Chappelle et al. 2016). Importantly, PTSD affects 7.7 million Americans (NIMH), with the major 
at-risk population being active military personnel, first responders, emergency responders, and 
abused individuals (Bowler, Han et al. 2010, Thomas, Wilk et al. 2010). While up to 17% of 
combat veterans are diagnosed with PTSD (Richardson, Frueh et al. 2010), well over 30% of 
veterans meet the criteria for a possible PTSD diagnosis. 
To further exacerbate the consequences of PTSD, multiple lines of evidence indicates 
significant comorbidity between PTSD and opioid use disorders (OUD). For example, heroin use 
disorder is associated with increased anxiety diagnoses (McHugh, Votaw et al. 2017) and can 
increase severity of PTSD symptoms in clinical populations (Jacobsen, Southwick et al. 2001, 




Heroin misuse leads to adverse consequences that persist long after cessation of drug use. The 
stress of withdrawal has been implicated in drug relapse (Koob and Volkow 2010), but may also 
increase vulnerability to other disorders such PTSD. Moreover, there is often a shared 
symptomology between opioid withdrawal and PTSD (Patel, Elmaadawi et al. 2017). While it is 
generally thought that PTSD precedes, and therefore is a risk factor, for substance use disorders, 
there is also evidence that a prior history of substance use exacerbates the development and 
symptoms of PTSD (Saladin, Brady et al. 1995, Bremner, Southwick et al. 1996, Jacobsen, 
Southwick et al. 2001, Holmes, Fitzgerald et al. 2012, McCauley, Killeen et al. 2012, Meier, 
Lambert-Harris et al. 2014, Patel, Elmaadawi et al. 2017). Consistent with this view, this 
suggests that the adverse symptoms that arise from substance use disorders, such as anxiety, 
depression, and poor coping skills, leave individuals biologically more vulnerable to the impact 
of severe stress and are thus more likely to develop PTSD (Jacobsen, Southwick et al. 2001, 
McCauley, Killeen et al. 2012). 
There are several animal models of PTSD (Yamamoto, Morinobu et al. 2009, Kaouane, 
Porte et al. 2012), and stress enhanced fear learning (SEFL) (Rau, DeCola et al. 2005), is an 
excellent model that effectively demonstrates  hyperreactivity to future fear learning. In this model, 
animals are exposed to 15 foot shocks, characterized as severe foot shock stress, in one context 
(Context A). One-week later animals are exposed to a single, more mild foot shock in a distinctly 
different context, (Context B). Severe stress in Context A significantly enhances fear learning to 
Context B. It is believed that neuroplastic changes occur following severe stress that lead to long-
term alterations of fear learning and changes how the animal processes subsequent fear challenges. 
This model is pronounced, robust, and reliable (Szczytkowski-Thomson, Lebonville et al. 2013, 




human PTSD. Although several animal models to study PTSD have been developed, the animal 
models needed to study heroin withdrawal are lacking. 
Few models of heroin withdrawal such as self-administration (Towers, Tunstall et al. 
2019, Gipson, Dunn et al. 2020) and precipitated withdrawal (Liu, Coller et al. 2011, Fatahi, 
Zeinaddini-Meymand et al. 2020) have been developed, however these models do not capture the 
clinical implications of heroin use disorder and withdrawal. The self-administration model, 
where a rodent is trained to press a lever to obtain self-administered intravenous injections of 
drug, has many advantages (Kmiotek, Baimel et al. 2012); however, the focus of our work is to 
examine the effects of heroin withdrawal, not the motivational aspects of heroin which requires 
self-administration. Furthermore, this model involves the animal receiving small doses of drug 
over a span of time. In order to reach a dependence level enough to produce a spontaneous 
opioid withdrawal, rodents must undergo ‘long-access’ self-administration cycles, often for 6 – 
24 hours (Shaham, Rajabi et al. 1996, Edwards, Graham et al. 2009). These small doses of opioid 
administration are not indicative of a clinical heroin addiction. On the other hand, a precipitated 
withdrawal involves the administration of an opioid antagonist, such as naloxone, which results 
in an immediate withdrawal. Our work is aimed at studying a spontaneous withdrawal to better 
understand the clinical consequences of opioid use disorder. In humans, heroin addiction is 
characterized by multiple phases of chronic drug use, spontaneous withdrawal, and relapse to 
drug-seeking behavior (Seip, Reed et al. 2012). Although the drug-seeking behavior of heroin is 
well characterized through the use of self-administration (De Vries, Schoffelmeer et al. 1998, 
Highfield, Yap et al. 2001, Leri and Stewart 2001, Kuntz, Patel et al. 2008, Zhou and Kalivas 
2008), little is known about heroin withdrawal. Neither the self-administration model nor the 




spontaneous withdrawal. Therefore, one of the goals of the present study was to test whether a 
chronic, escalating heroin administration and spontaneous withdrawal paradigm would produce a 
reliable heroin withdrawal animal model. 
Given that heroin withdrawal can produce similar physiological responses as those 
induced by stress, the second goal of the present study was to test whether heroin withdrawal 
may enhance fear learning in the same way as a severe stressor. The current studies test the 
overarching hypothesis that heroin withdrawal substitutes for a severe stressor in the SEFL 
model to produce enhanced fear learning. To this end, Experiment 1 tested whether a chronic, 
escalating heroin administration and spontaneous withdrawal would produce withdrawal 
behaviors, and in turn a novel animal model of heroin withdrawal. Subsequently, Experiment 2 
determined whether heroin withdrawal can produce enhanced fear learning. Collectively, these 
experiments are the first to test whether chronic escalating heroin administration and 
spontaneous withdrawal can sensitize future fear learning. 
MATERIALS AND METHODS 
Animals 
Adult male Sprague Dawley rats (225-250g, Charles River Laboratories, Raleigh, NC) 
were individually housed under a reversed 12-hour light-dark cycle, given ad libitum access to 
food and water, and handled regularly throughout experimentation. All procedures were 
conducted in accordance with federal guidelines and with approval from the University of North 
Carolina at Chapel Hill Institutional Animal Care and Use Committee. 
Experiment 1: Effect of Chronic Escalating Heroin Administration on Withdrawal Behaviors 
Drug Administration: Animals were randomly assigned to two groups (chronic heroin 




[diacetylmorphine hydrochloride, National Institute on Drug Abuse (NIDA) Drug Supply 
Program, Bethesda, MD, USA] was dissolved in sterile 0.9% saline to final concentrations of 
1.0, 2.5, 5.0, 7.5, and 10.0 mg/mL, and stored at 4°C until time of injection. Injections were 
administered subcutaneously (SC). The administration schedule of chronic escalating heroin 
(adapted from (Zhou, Bendor et al. 2006, Seip, Reed et al. 2012, Zhou, Leri et al. 2013)) 
consisted of 10-days of three injections over 24-hour periods (at 15:00, 21:00, and 9:00 the next 
day, UTC-05:00) and a dose increase every other day: 3.0 (3 x 1.0) mg/kg/day on days 1-2, 7.5 
(3 x 2.5) mg/kg/day on days 3-4, 15.0 (3 x 5.0) mg/kg/day on days 5-6, 22.5 (3 x 7.5) mg/kg/day 
on days 7-8, and 30 (3 x 10) mg/kg/day on days 9-10 (Figure 1a). Animal weight change, a 
quantifiable and reliable measure of opioid withdrawal (Gellert and Holtzman 1978), was 
measured at every dose increase and subsequent withdrawal time point. 
Procedure Rodent withdrawal behaviors were quantified following the chronic 
escalating heroin administration. Animals were randomly assigned to receive heroin (n=12) or 
saline (n=8) throughout the procedure. Twenty-four hours into withdrawal, animals were placed 
into open-field Plexiglas boxes (42cm x 42cm x 30cm). Withdrawal behaviors (rearing, wet dog 
shakes, teeth chattering, and diarrhea) were video-recorded for 30 min. Experimenters were 
trained on withdrawal behaviors, until there was 98% agreement in observation scores. 
Experimenters scored behaviors blind to treatment condition. Positive withdrawal behavior was 
recorded if the behavior occurred at least once in the 30 min observation period. A heroin 
withdrawal score was calculated for each behavior based on the number of behaviors observed 
during the 30 min observation period, and these individual behavior scores were summed to 





Experiment 2: Effect of Heroin Withdrawal on Fear Learning 
Heroin Withdrawal-Enhanced Fear Learning (HW-EFL): We used a modified 
version of the SEFL model previously described (Rau, DeCola et al. 2005, Szczytkowski-
Thomson, Lebonville et al. 2013, Jones, Lebonville et al. 2015, Jones, Lebonville et al. 2017). 
Rather than a severe foot shock, animals underwent heroin withdrawal in their home cage. 
Control animals received saline administration and were kept in the home cage. Seven days after 
the start of withdrawal, animals were placed into a novel context for 15 min and video recorded 
for baseline activity (Test Day B). The novel context (Med Associates, St. Albans, VT) was 
housed in a separate room and had a distinct textile, olfactory, and auditory characteristics, as 
previously described (Szczytkowski-Thomson, Lebonville et al. 2013). On Day 8, animals were 
placed into the same context for a single scrambled foot shock (1mA, 1s) at 3 min, 12 s. On days 
9, 10, 15, 22 (Test Days 1, 2, 7, and 14) animals are placed into the same context for 8 min, 32 s 
and were video recorded to measure freezing behavior, a measure of learned fear. Automated 
video tracking and analysis software was used to quantify percent freezing behavior in all 
sessions (Ethovision XT, Activity Analysis Feature with Threshold=10, Noldus Information 
Technology Inc., Netherlands). 
Procedure: The effect of heroin withdrawal was examined on enhanced fear learning. 
Animals were randomly assigned to receive heroin (n=15), or saline (n=16) and underwent the 
chronic escalating heroin administration and subsequently exposed to heroin withdrawal-
enhanced fear learning. 
Statistical Analysis 
For Experiment 1, withdrawal behaviors were analyzed using a χ2 test. Body weight on 




(Drug Treatment) x 6 (Day) repeated measures ANOVA. Weight change and composite 
withdrawal scores were analyzed using an unpaired, two-tailed Student’s t-test. For Experiment 
2, a one-way (Heroin, Saline) ANOVA was used to analyze baseline freezing data. A 2 (Heroin, 
Saline) x 4 (Test Day) repeated measures ANOVA was used to analyze freezing behavior across 
test days. 
RESULTS 
Experiment 1: Chronic Escalating Heroin Administration Produces a Reliable Withdrawal 
The chronic escalating heroin administration (Figure 1A) produced withdrawal behaviors 
24 hours after the last heroin dose. χ2 analysis revealed no difference between the heroin 
withdrawal and saline controls for rearing behavior (χ2(1,n=20)=1.319, p=.251). Importantly, χ2 
analysis revealed significant increases in withdrawal behaviors between the heroin withdrawal 
and saline controls for wet dog shakes (χ2(1,n=20)=13.333, p<.001), teeth chattering 
(χ2(1,n=20)=5.714, p=.017), and diarrhea (χ2(1,n=20)=5.714, p=.017) (Figure 1b). A one-way 
ANOVA revealed no significant differences between heroin and saline animal weights on Day 1, 
(F(1,29)=.645, p=.428), indicating no pre-existing weight differences between groups. Importantly, 
a repeated measures ANOVA revealed a significant main effect of drug-treatment on weight 
between days 3-10, (F(1,29)=127.937, p<.001), indicating that heroin-treated animals have 
decreased weight compared to saline-treated controls. There was also a significant main effect 
across days (F(5,145)=705.236, p<.001) and significant day by drug treatment interaction 




10 and Day 11 (first 24 hours of withdrawal) revealed that heroin-treated animals lost 
significantly more weight than saline-treated animals (t(29)=10.666, p<.001) (Figure 1c). 
 
Student’s t-test comparing composite withdrawal scores between heroin-treated animals 
and saline-treated animals revealed that heroin-treated animals had a significantly higher 
composite withdrawal score than saline-treated animals (t(18)=-9.754, p<.001) (Figure 2b). 
Furthermore, the range of heroin withdrawal scores was between 6 and 14, with no outliers, 
suggesting that all animals experienced a relatively similar range of withdrawal after the chronic 





Figure 1. Chronic escalating heroin administration produces withdrawal. Chronic 
escalating heroin administration schematic (A). Withdrawal behavior (B). Overall body 
weight across days of heroin administration and weight change in 24-hour withdrawal (C) *, 





Experiment 2: Heroin Withdrawal Produces Enhanced Fear Learning 
Heroin withdrawal substituted for the severe stressor in the SEFL model, and produced 
subsequent enhanced fear learning. There was no effect of drug treatment on baseline freezing to 
the context, (F(1,16)=1.209, p=.288). Importantly, a 2 x 4 repeated measures ANOVA revealed a 
significant main effect of drug treatment, (F(1,16)=7.389, p=.015), indicating the exciting finding 
that a history of heroin withdrawal enhances fear learning to a single shock experience. There 
was also a significant main effect of day, (F(3,48)=14.222, p<.001), indicating that indicating that 






Figure 2. Chronic escalating heroin administration produces a similar range of withdrawal 
Withdrawal composite score explanation chart (A). Heroin animals have a higher withdrawal 
composite score (range between 6 and 14) than saline animals (range between 0 and 2) (B). *, 






The current studies demonstrate for the first time that exposure to chronic escalating 
heroin administration produces heroin withdrawal in a rat. Previously our laboratory and others 
have established that the severe stress of inescapable foot shock causes the development of 
enhanced fear learning (Rau, DeCola et al. 2005, Szczytkowski-Thomson, Lebonville et al. 
2013). Here, we show that the chronic heroin administration and spontaneous withdrawal is 
capable of producing a PTSD-like phenotype in a rodent model. These studies suggest that 
severe foot shock stress and heroin withdrawal may act similarly to alter enhanced fear learning. 
Collectively, these findings provide new evidence that heroin withdrawal, similar to a severe 
stressor, can lead to the development of future enhanced fear learning. 
 
Figure 2. Heroin withdrawal causes similar enhanced fear learning as a severe stressor. 
Experimental timeline (A). Heroin withdrawal significantly enhances contextual freezing 
behavior to a single mild footshock (B). *, statistically significant difference relative to 




In the present study, exposure to chronic escalating heroin administration produces a 
reliable withdrawal in rats. The focus of the present work was to examine the effects of heroin 
withdrawal, not the motivational aspects of heroin, and therefore we chose to develop an 
experimenter-administration of heroin versus a self-administration of heroin. The chronic, 
escalating doses of experimenter-administered heroin reliably result in the development of 
spontaneous withdrawal upon cessation of drug administration (Zhou, Leri et al. 2013), which is 
not reliably achieved with self-administration. Importantly, the chronic, escalating dosing 
regimen and spontaneous withdrawal is in fact reflective of the human condition of heroin 
misuse (Seip, Reed et al. 2012, Zhou, Leri et al. 2013). This model mimics the multiple and 
escalating doses that are taken by heroin-dependent individuals to prevent symptoms of 
withdrawal (Kreek, L et al. 2002). Furthermore, Kreek and colleagues have also shown that the 
spontaneous withdrawal produced by a similar model induces the expression of genes in the 
brain that are associated with stress responses (Zhou, Leri et al. 2013). We believe that this 
approach, while not encapsulating drug motivation per se, offers a strength over self-
administration, with greater face, construct and predictive validity as a means to examine the 
neural consequences of heroin withdrawal on stress-enhanced fear learning. 
Opioid withdrawal is often associated with increased stress-sensitivity, and therefore 
managing stress and anxiety becomes a major focus of treatment in clinical populations 
(Carcoba, Contreras et al. 2011). There have been various studies that have shown a connection 
between morphine withdrawal and increased anxiety in both humans and animals (Bhattacharya, 
Chakrabarti et al. 1995, Schulteis and Koob 1996, Koob and Le Moal 1997, Koob 2008). This 
suggests that withdrawal states can lead to a stress response and that opioid withdrawal may 




morphine withdrawal results in the activation of the HPA axis, specifically, corticotropin-
releasing hormone mRNA is increased following a precipitated morphine withdrawal (McNally 
and Akil 2002, Houshyar, Gomez et al. 2003, Nunez, Foldes et al. 2007). This long-lasting 
activation within the HPA axis and stress response leads us to believe that an individual may be 
more susceptible to develop anxiety-like disorders such as PTSD. 
 Here, we demonstrate that exposure to heroin withdrawal is shown to produce a PTSD-
like phenotype in a rodent model. PTSD, alone, is a severe psychological disorder, and to further 
exacerbate the consequences of PTSD, multiple lines of evidence indicate that opiate misuse 
leads to increased incidence and severity of PTSD. Consistently, opiate use disorder has emerged 
as a significant issue in clinical populations with PTSD due to prolonged pain treatments with 
opiates following active duty (Bennett, Elliott et al. 2017, Finley, Schneegans et al. 2018). The 
current findings provide strong and novel evidence that heroin use and withdrawal can lead to an 
exacerbated PTSD-like phenotype. 
 Our studies suggests that severe foot shock stress and heroin withdrawal may act through 
similar mechanisms to produce altered enhanced fear learning, however, the mechanism through 
which heroin withdrawal induces alterations in future fear learning is not known. We have 
previously shown that the severe stressor in SEFL induces a time-dependent, region-specific 
increase in dorsal hippocampal (DH) interleukin-1β (IL-1β), a cytokine responsible for learning 
and memory, and subsequent fear learning is blocked by DH IL-1 receptor antagonism (IL-1RA) 
(Jones, Lebonville et al. 2015, Jones, Lebonville et al. 2017, Jones, Paniccia et al. 2018). This 
suggests that stress-induced dorsal hippocampal interleukin-1β signaling is critical to the 
development of SEFL. Future studies could investigate whether the same neurobiological 




In summary, our findings demonstrate that exposure to chronic escalating heroin 
administration produces a heroin withdrawal animal model. Furthermore, exposure to chronic 
heroin administration and spontaneous withdrawal is capable of producing a PTSD-like 
phenotype in rats. Collectively, these data provide important new evidence that chronic heroin 
administration and withdrawal can alter learning and memory processes. These data may lead to 
future experiments that may provide a possible mechanism that contributes to the similarities in 
symptomology and overwhelming comorbidity of opiate use disorders and PTSD.  
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